Preparing for Hong Kong's OTC derivatives licensing regime: practical steps to take now

Hong Kong's forthcoming OTC derivatives licensing regime is expected to take effect in the second half of 2027, subject to the legislative process. While implementation may still be some way off, firms active in OTC derivatives should start assessing whether their activities, licences, governance arrangements and capital planning will be affected.

Key areas for review include whether Type 11, Type 12, expanded Type 7 or expanded Type 9 may apply, whether transitional arrangements or exclusions are available, and what changes may be needed to policies, controls, booking arrangements, staff competence and financial resources planning.
 

What is changing?

The new regime is expected to bring certain OTC derivatives activities within Hong Kong's licensing perimeter.

This regime may affect firms dealing in, advising on, clearing, operating automated trading services for, or managing portfolios involving OTC derivatives. The precise licensing impact will depend on the firm’s role, product scope, client interaction and operating model.
 

What early assessment matters

Although commencement is expected in the second half of 2027, firms may find that it extends beyond licensing analysis. Internal governance reviews, financial planning and operational processes may all require review, making early assessment critical to implementation planning.
 

Implications for firms

• Transitional arrangements for licensing: The transitional arrangements may provide temporary relief for eligible firms, but the application or notification route, timing and eligibility requirements should be assessed carefully.

• Financial resources rules transitional arrangements: The FRR transitional arrangements may have important capital planning implications, particularly for firms with existing OTC derivatives activities or those seeking deemed licensed status.

• Booking arrangements, governance and controls: Firms should consider whether their current booking model, client-facing arrangements, governance framework and internal controls remain appropriate under the proposed regime.

Practical readiness checklist

• Map current and planned OTC derivatives activities against the new and expanded regulated activities.

• Confirm whether licensing, registration, notification or transitional arrangements may apply.

• Assess the impact on Financial Resources Rules requirements, governance, booking arrangements and internal controls.

• Review staff competence, client-facing processes, policies, procedures and compliance monitoring arrangements.

• Develop a practical implementation plan with clear ownership, milestones and senior management oversight.

Conclusion

The OTC derivatives licensing regime is expected to be a significant development for Hong Kong market participants. Firms that begin assessing the implications early will be better placed to identify regulatory gaps, manage implementation risks and support effective senior management oversight as the framework develops.

How Ocorian can help

We work with firms to navigate the practical implications of regulatory change and prepare for implementation in a proportionate and structured way. Our support includes

• Conducting a structured scope and gap assessment.

• Advising on the appropriate licensing, registration or notification route.

• Assessing FRR, governance and booking arrangement implications.

• Reviewing policies, procedures and implementation plans.

• Preparing documentation for senior management and regulatory engagement.

If you would like to obtain the key points of the OTCD regime or discuss how the proposed changes may affect your business, please contact us. We would be pleased to support your readiness assessment.

For an overview of the key regulatory changes and the areas they will affect, please download our guide below: